Context Therapeutics: CTIM-76 hits 29% ORR in ovarian cancer
Context Therapeutics has reported interim Phase 1 data for CTIM-76, its claudin-6 (CLDN6) x CD3 T cell engaging bispecific antibody, showing a 29% confirmed overall response rate in patients with platinum-resistant ovarian cancer. The data, cut off as of 29 May 2026, come from an ongoing dose-escalation study in a heavily pretreated population with a median of seven prior lines of therapy.
Of seven efficacy-evaluable PROC patients dosed at 140µg to 280µg weekly, two achieved confirmed partial responses per RECIST v1.1. A further two patients achieved stable disease, giving a disease control rate of 57%. Three patients who reached confirmed stable disease or partial response maintained that benefit for at least six months, a meaningful durability signal in a population that has typically exhausted most standard options.
Safety and pharmacokinetics
The safety profile from the weekly dosing schedule was broadly consistent with the expected mechanism of action for a T cell engager. Cytokine release syndrome, the most closely watched adverse event class for this modality, was limited to Grade 1 in 11% of PROC patients at active dose levels. The company said this rate may support outpatient dosing in future trials, which would be a practical advantage for patients and healthcare systems alike. Most adverse events were Grade 1 or Grade 2, occurred during the first or second dose, and resolved with standard management.
Pharmacokinetic data showed approximately dose-proportional increases in exposure, and Context said the preliminary PK profile supports exploration of a three-weekly (Q3W) dosing schedule in the second half of 2026. The 560µg weekly dose exceeded target exposures and was not continued.
Martin Lehr, chief executive of Context Therapeutics, said the weekly administration "produced compelling anti-tumour activity and a well-tolerated safety profile in heavily pretreated patients, many of whom had extensive prior exposure to antibody-drug conjugates." He added that Q3W data are expected to inform a Phase 1b dose-expansion study planned for 2027.
Market context and competitive landscape
CTIM-76 has FDA Fast Track Designation in platinum-resistant ovarian cancer, a regulatory status that affords more frequent agency interactions and rolling review eligibility but does not guarantee approval. The designation reflects the significant unmet need in PROC, where response rates to late-line chemotherapy are typically low and duration of response limited.
The CLDN6-targeting space has attracted growing interest. BioNTech's BNT211, a CLDN6-targeted CAR-T combined with a CLDN6-encoding RNA vaccine, has shown activity in heavily pretreated solid tumours, and several other companies are pursuing claudin-family targets across CLDN6, CLDN18.2, and related epitopes. Context is positioning CTIM-76 as a potentially best-in-class CLDN6 T cell engager, citing its preclinical low-immunogenicity profile and what it describes as scalable manufacturing, though the company has not published head-to-head comparator data. The move to Q3W dosing, if validated, could differentiate CTIM-76 from weekly-dosed competitors on patient convenience.
The broader bispecific antibody field in solid tumours remains early. Unlike haematological malignancies, where CD3-engaging bispecifics have reached approval, solid tumour programmes face additional challenges including antigen heterogeneity, the immunosuppressive tumour microenvironment, and on-tumour versus off-tumour target expression. A 29% ORR in a population with a median of seven prior lines is an encouraging signal, but investors and clinicians will look for durability data from larger cohorts and the Q3W schedule before drawing firm conclusions about CTIM-76's commercial trajectory.